Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Featured Article from MarketBeat Media Pfizer Adds to Its Big Bet on Weight Loss DrugsWritten by Jordan Chussler. Published 12/16/2025. 
Key Points - The health care sector has led the S&P 500 over the three months, but Pfizer has lagged of late, slipping 5% since the start of October.
- As the Big Pharma company continues to struggle to replace COVID-19 vaccine revenue, it is heavily learning into the semaglutide and GLP-1 weight loss drug trend.
- Last week, the company signed a $2.1 billion licensing agreement with a Chinese pharma company to develop its early-stage weight loss pill.
Health care stocks have been on a run lately, leading the S&P 500's 11 sectors over the past three months with a gain of 11.55%. Unfortunately for some investors, that recent rally has not included all of the Big Pharma mainstays. Pfizer (NYSE: PFE), the maker of Chantix, Eliquis and Paxlovid, has seen its shares slide 5% since the start of October. By comparison, other mega-cap pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Regeneron Pharmaceuticals (NASDAQ: REGN), and Eli Lilly (NYSE: LLY) are up nearly 14%, 24%, and 25%, respectively, over the same time frame. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> And despite Pfizer making headlines on Nov. 13 after acquiring obesity biotech Metsera in a $10 billion deal, the stock has only mustered a 0.23% gain since then. But the nearly 177-year-old biopharma company is once again looking to expand its role in the weight-loss drug market, with management and shareholders alike hoping that doing so can help recover revenue lost as demand for mRNA-based COVID-19 vaccines wanes. Pfizer Looks to Gain Market Share After Enormous Deal With YaoPharma On Tuesday, Dec. 9, Pfizer struck a $2.1 billion licensing deal with China's YaoPharma to develop a GLP-1 weight-loss pill that is in early-stage development. The drug works similarly to Wegovy, the game-changing weight-loss injection from competitor Novo Nordisk (NYSE: NVO). News of a yet-to-be-approved pill may not be enough to move the stock in the short term; however, it does reflect the company's commitment and momentum in the obesity-treatment market. The agreement calls for Pfizer to pay a $150 million upfront fee to YaoPharma's parent company, Shanghai Fosun Pharmaceutical, which has an $8.4 billion market cap. Additionally, Pfizer could pay YaoPharma up to $1.94 billion in milestone payments if progress toward approval is demonstrated, along with royalty payments on sales should the drug reach the market. Those milestone payments will be contingent on YaoPharma successfully navigating the weight-loss pill through phase one trials, after which Pfizer will take control of later-stage development. Pfizer also plans to conduct combination studies — currently in mid-stage development — using the Chinese company's pill alongside its own GIP-targeting compound, a strategy similar to Eli Lilly's approach with Zepbound and Mounjaro that targets both GLP-1 and GIP. Pfizer Is Positioning Itself for the Future of the Weight-Loss Drug Market The deal underscores how aggressively the company's executive team is pursuing a more prominent, long-term position in the GLP-1 and broader obesity-treatment market. Pfizer's leadership has shown a willingness to invest roughly $10.1 billion over the past month as it targets a rapidly growing industry. Forecasts from market analysis firm Grand View Research suggest the GLP-1 weight-loss drug market is expected to grow at a compound annual growth rate (CAGR) of 18.54% from 2025 to 2030, rising from under $14 billion this year to an estimated $48.84 billion by 2030. Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While alternative obesity interventions exist — including lifestyle modifications and bariatric surgery — GLP-1 drugs remain the preferred option among many physicians and patients. Patient Investors Can Enjoy PFE's Sizable Dividend Shareholders are hoping Pfizer's push into the weight-loss drug market proves fruitful after the stock has punished loyal investors, losing more than 31% over the past five years. Much of that decline stems from falling COVID-vaccine sales, which caused the company's revenue growth to fall from more than 95% at the end of 2021 to a decline of more than 41% by the end of 2023. Last year, Pfizer rebounded marginally, registering a nearly 7% increase in revenue. At the same time, the stock's dividend yield has helped to offset some investors' concerns. Pfizer remains a strong dividend payer with a current yield of 6.65% — or $1.72 per share annually. That payout has increased for 16 consecutive years, making the stock a favorite among income investors despite a high payout ratio that raises some eyebrows. For investors unconcerned with immediate capital gains but bullish on the near- and mid-term prospects of prescription weight-loss drugs, Pfizer can continue to provide income while serving as a speculative position in the GLP-1 industry. However, growth-focused investors might be wary after another year of underperformance. Analysts' average 12-month price target implies roughly 10% potential upside from the stock's current price and comes with a consensus Hold rating. Meanwhile, short interest has been steadily rising as the stock continues to attract Wall Street's bears. Currently, about $3.58 billion of the float is shorted — nearly 84% more than PFE's short position at the end of January 2025.
| 
